Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amneal Pharmaceuticals, Inc. - Class A Common Stock (NQ:AMRX)

7.515 +0.015 (+0.20%)
Streaming Delayed Price Updated: 10:09 AM EDT, May 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 123,454
Open 7.500
Bid (Size) 7.510 (7)
Ask (Size) 7.520 (14)
Prev. Close 7.500
Today's Range 7.450 - 7.552
52wk Range 6.290 - 9.475
Shares Outstanding 1,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AMRX Q1 Earnings Call: Miss on Revenue, Margin Expansion, and Product Pipeline Progress
Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) fell short of the market’s revenue expectations in Q1 CY2025, but sales rose 5.5% year on year to $695.4 million. On the other hand, the... 
Via StockStory
Topics Supply Chain
Exposures Supply Chain
Amneal Gets FDA Nod For Self-Administrable Migraine Injection
The company said the injection is the first and only dihydroergotamine (DHE) autoinjector for treating migraine and cluster headaches. 
Via Stocktwits
Topics Data Breach
Exposures Information Security Product Safety

Performance

YTD
-3.2%
-3.2%
1 Month
+5.4%
+5.4%
3 Month
-3.5%
-3.5%
6 Month
-9.8%
-9.8%
1 Year
+11.7%
+11.7%

More News

Read More
Amneal Receives U.S. FDA Approval for Brekiya® (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
3 Russell 2000 Stocks in Hot Water
Via StockStory
Amneal and Apiject to Expand Sterile and Blow-Fill-Seal (BFS) Capabilities for Advanced Pharmaceutical Manufacturing in the U.S.
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
3 Value Stocks in Hot Water
Via StockStory
Topics Supply Chain
Exposures Supply Chain
3 Small-Cap Stocks Facing Headwinds
Via StockStory
Drug Maker Amneal Highlights Strong Commercial Uptake For Parkinson's Drug But Q1 Earnings Are Mixed
Via Benzinga
Amneal (NASDAQ:AMRX) Misses Q1 Sales Targets, Stock Drops 11.3%
Via StockStory
Amneal Reports First Quarter 2025 Financial Results
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Earnings Scheduled For May 2, 2025
Via Benzinga
Examining the Future: Amneal Pharmaceuticals's Earnings Outlook
Via Benzinga
Amneal (AMRX) To Report Earnings Tomorrow: Here Is What To Expect
Via StockStory
3 Profitable Stocks Skating on Thin Ice
Via StockStory
Generic Pharmaceuticals Stocks Q4 Teardown: Viatris (NASDAQ:VTRS) Vs The Rest
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
2 Reasons to Avoid AMRX and 1 Stock to Buy Instead
Via StockStory
Topics Economy Government Stocks
Exposures Economy Political Tariff
3 of Wall Street’s Favorite Stocks That Concern Us
Via StockStory
Amneal Donates $1.5 Million to Support Patients During Parkinson’s Awareness Month
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal to Report First Quarter 2025 Results on May 2, 2025
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal's Combination Drug Shows Improved Sleep Quality In Parkinson's Disease Patients
Via Benzinga
Amneal Announces New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Parkinson’s Disease
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Announces Expanded Coverage for CREXONT® (Carbidopa and Levodopa) to Enhance Access for Parkinson’s Disease Patients in the U.S.
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Launches BORUZU™, First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Q4 Earnings Highs And Lows: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs The Rest Of The Generic Pharmaceuticals Stocks
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Amneal to Participate at Upcoming Investor Conference
From Amneal Pharmaceuticals, Inc.
Via Business Wire

Frequently Asked Questions

Is Amneal Pharmaceuticals, Inc. - Class A Common Stock publicly traded?
Yes, Amneal Pharmaceuticals, Inc. - Class A Common Stock is publicly traded.
What exchange does Amneal Pharmaceuticals, Inc. - Class A Common Stock trade on?
Amneal Pharmaceuticals, Inc. - Class A Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Amneal Pharmaceuticals, Inc. - Class A Common Stock?
The ticker symbol for Amneal Pharmaceuticals, Inc. - Class A Common Stock is AMRX on the Nasdaq Stock Market
What is the current price of Amneal Pharmaceuticals, Inc. - Class A Common Stock?
The current price of Amneal Pharmaceuticals, Inc. - Class A Common Stock is 7.515
When was Amneal Pharmaceuticals, Inc. - Class A Common Stock last traded?
The last trade of Amneal Pharmaceuticals, Inc. - Class A Common Stock was at 05/20/25 10:09 AM ET
What is the market capitalization of Amneal Pharmaceuticals, Inc. - Class A Common Stock?
The market capitalization of Amneal Pharmaceuticals, Inc. - Class A Common Stock is 7.51K
How many shares of Amneal Pharmaceuticals, Inc. - Class A Common Stock are outstanding?
Amneal Pharmaceuticals, Inc. - Class A Common Stock has 8K shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.